A method for sterilization of human plasma and platelets

Information

  • Research Project
  • 6662699
  • ApplicationId
    6662699
  • Core Project Number
    R44HL062729
  • Full Project Number
    5R44HL062729-04
  • Serial Number
    62729
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/1999 - 25 years ago
  • Project End Date
    8/31/2004 - 20 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    9/1/2003 - 21 years ago
  • Budget End Date
    8/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    4
  • Suffix
  • Award Notice Date
    8/11/2003 - 21 years ago

A method for sterilization of human plasma and platelets

DESCRIPTION (provided by applicant): This proposal is to develop a method to prolong the shelf-life and increase the safety of human platelets with a unique method of sterilization. The method delivers an agent known to kill a range of microbial pathogens in vitro including many bacterial species known to contaminate platelet concentrates, fungi, parasites, and viruses. The lethal agent can be released from an insoluble polymer that can be incorporated into the plastic that comprises the collection bag. The microbicide breaks down rapidly to normal physiological by-products, presenting little danger to the patient. Successful development of this method will increase the safety of the platelet and plasma supply, and, by inhibiting microbial growth, increase the shelf-life of platelets. The focus of the effort will be to develop a storage container made from polymers that release sufficient quantities of the lethal agent. Alternative strategies include increasing the polymer surface area, via alterations in the storage container, that will allow release of sufficient lethal agent for efficacy. Antimicrobial spectra of the lethal agent will continue to be assessed before and during prototype stages. Physiological assessments of the effects of the lethal agent on platelets will be performed. Prototype containers will be tested under blood bank conditions. PROPOSED COMMERCIAL APPLICATION: Not Available

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    207500
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:207500\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AMULET PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    Rockville
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20850
  • Organization District
    UNITED STATES